Nestle steps up push into medicine with €100m milk allergy test deal

Nestle, the world’s biggest food company, is stepping up its push into medicine with a global deal worth up to €100m to develop and market an experimental milk allergy test for infants.

The Swiss group will pay DBV Technologies €10m upfront for rights to its skin patch test for cow’s milk protein allergy (CMPA), with the balance depending on successful development, the two companies said yesterday.

Shares in the French biotech company rose 5% on the news.